LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that represents a promising target for the treatment of several metabolic diseases. Administration of recombinant wild type FGF21 to diabetic animals leads to a dramatic improvement in glycaemia and ameliorates other systemic measures of metabolic health. Here we report the pharmacologic outcomes observed in non-human primates upon administration of a recently described FGF21 analogue, LY2405319 (LY). Diabetic rhesus monkeys were treated subcutaneously with LY once daily for a period of seven weeks. The doses of LY used were 3, 9 and 50 mg/kg each delivered in an escalating fashion with washout measurements taken at 2, 4, 6 and 8 weeks following the final LY dose. LY therapy led to a dramatic and rapid lowering of several important metabolic parameters including glucose, body weight, insulin, cholesterol and triglyceride levels at all doses tested. In addition, we observed favorable changes in circulating profiles of adipokines, with increased adiponectin and reduced leptin indicative of direct FGF21 action on adipose tissue. Importantly, and for the first time we show that FGF21 based therapy has metabolic efficacy in an animal with late stage diabetes. While the glycemic efficacy of LY in this animal was partially attenuated its lipid lowering effect was fully preserved suggesting that FGF21 may be a viable treatment option even in patients with advanced disease progression. These findings support continued exploration of the FGF21 pathway for the treatment of metabolic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, despite weight loss and addition of medications, the disease progressed based on a continuous increase in HbA1c133.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, those in the intensive lifestyle arm with a history of cardiovascular event at baseline demonstrated a tendency for an increased risk of a subsequent cardiovascular event133”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
In the citing paper
“Despite differential weight loss for over 10 years and improvements in many cardiovascular risk factors, including blood pressure and lipids, lifestyle change did not reduce cardiovascular events compared to diabetes support and education (control)133.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“Recently our group and others have reported FGF21-induced regulation of the circulating levels and improved total body sensitivity to a multitude of other metabolic factors such as insulin, leptin and adiponectin highlighting one of the major mechanisms of FGF21 in vivo action [7,9,15,17].”
BackgroundSelf-citationXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · cited 1×
“Indeed, administration of recombinant wild type FGF21 to diabetic rodents leads to a rapid and robust lowering of hyperglycemia, improvements in circulating/tissue lipid levels and reduced body weight [8–11].”
BackgroundFibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · cited 1×
“Recently our group and others have reported FGF21-induced regulation of the circulating levels and improved total body sensitivity to a multitude of other metabolic factors such as insulin, leptin and adiponectin highlighting one of the major mechanisms of FGF21 in vivo action [7,9,15,17].”
BackgroundSelf-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847 · cited 1×
“One example of this new class of molecules is fibroblast growth factor 21 (FGF21) [3,4], which recently emerged as a promising agent able to simultaneously correct many if not all abnormalities in metabolically compromised animals [5–7].”
BackgroundThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · cited 7×
“Similar to the effects observed with administration of wild type FGF21 in rodents [7–9] and in primates [12,15], all monkeys experienced progressive weight loss during each dosing phase amounting to 12.”
BackgroundResultInfluentialSelf-citationLin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“Given that FGF21 is unable to lower glucose in adiponectin null mice [22,23] one can surmise that the increase in adiponectin is explicitly required for FGF21s glycemic effect.”
BackgroundAdiponectin: mechanistic insights and clinical implications
Turer, A. T., & Scherer, P. E. (2012) · Diabetologia · doi:10.1007/s00125-012-2598-x · Cited by 632 · cited 1×
“Here we demonstrate that treatment with LY also leads to a rapid and robust induction of adiponectin, a known insulin sensitizer [21].”
BackgroundAn FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice
Holland, W. L., Adams, A. C., Brozinick, J. T., Bui, H. H., Miyauchi, Y., Kusminski, C. M., Bauer, S. M., Wade, M., Singhal, E., Cheng, C. C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.019 · Cited by 535
Self-citationβKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2009 · Cited by 340 · cited 1×
“One example of this new class of molecules is fibroblast growth factor 21 (FGF21) [3,4], which recently emerged as a promising agent able to simultaneously correct many if not all abnormalities in metabolically compromised animals [5–7].”
Background
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Animal models of obesity and diabetes mellitus
Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 832
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885
Self-citationTargeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496
“Consistent with previous observations in NHPs (Adams et al., 2013), circulating adiponectin (Figure 2G) was increased.”
BackgroundResultInfluentialNon-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
FGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 324
“…in insulin-resistant rodents and in obese diabetic nonhuman primates (Kharitonenkov et al, 2007; Berglund et al, 2009; Hale et al, 2012; Hecht et al, 2012; Véniant et al, 2012; Adams et al, 2013; Camporez et al, 2013; Emanuelli et al, 2014; Charoenphandhu et al, 2017; Stanislaus et al, 2017).”
BackgroundTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Kliewer, S. A., & Mangelsdorf, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.004 · Cited by 277
“Interestingly, however, FGF21 decreases food intake in obese monkeys (Adams et al., 2013; Talukdar et al., 2016b; Thompson et al., 2016).”
BackgroundLin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., Jin, L., Lian, Q., Huang, Y., Ding, H., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015308 · Cited by 271
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
“Nonetheless, initial drug candidates for obesity have limited efficacy and/or cause unacceptable adverse effects (Adan, 2013; Rodgers et al., 2012; Scheen and Van Gaal, 2014).”
BackgroundTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 213
Inventing new medicines: The FGF21 story
Kharitonenkov, A., & Adams, A. C. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.003 · Cited by 198
“Given that onset of glucose lowering was significantly faster in a follow up diabetic monkey study when much higher doses of an FGF21 analog, LY2405319, were used [41], the timing of FGF21 administration and the dose required to induce a meaningful glucose lowering effect appear to be interdependent.”
BackgroundResultInfluentialSelf-citationAction and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“Chronic administration of the FGF-21 analog LY2405319 reduced body weight, triglycerides and improved glucose metabolism in diabetic non-human primates and humans [77,78] in association with dose-dependent elevation of plasma adiponectin [78].”
BackgroundGoing Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 166
Brown, Beige, and White: The New Color Code of Fat and Its Pharmacological Implications
Pfeifer, A., & Hoffmann, L. S. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124346 · Cited by 163
FGF21-based pharmacotherapy – potential utility for metabolic disorders
Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.001 · Cited by 163
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13023 · Cited by 145
“In obese monkeys, FGF21 analogues decrease body weight and triglycerides (TGs).(2,4,8,9) Changes in glycaemic endpoints, however, vary according to species A.”
BackgroundAutophagy and Non-Alcoholic Fatty Liver Disease
Lavallard, V. J., & Gual, P. (2014) · BioMed Research International · doi:10.1155/2014/120179 · Cited by 134
Serum FGF21 levels are associated with brown adipose tissue activity in humans
Hanssen, M. J. W., Broeders, E., Samms, R. J., Vosselman, M. J., van der Lans, A. A. J. J., Cheng, C. C., Adams, A. C., van Marken Lichtenbelt, W. D., & Schrauwen, P. (2015) · Scientific Reports · doi:10.1038/srep10275 · Cited by 131
Self-citationLatest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
“In contrast, weight loss observed in primates by a modified FGF21 protein derivative known as LY2405319 is primarily mediated via a reduction in food intake, suggesting that the mechanism of action may be different across species [130-132].”
Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J., & Rolph, T. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100057 · Cited by 131
“Mean SBP, mmHg (SD) 125 (12) 118 (11) 126 (16) 119 (14) 125 (13) 121 (18) 129 (12) 120 (17) 132 (19) 126 (18)”
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123
Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans
Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., & Plomgaard, P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.001 · Cited by 123
“In addition, FGF-21 administration improves plasma lipid profile in mice and rhesus monkeys [2,52].”
BackgroundHyperlipidemia and hypothyroidism
Su, X., Peng, H., Chen, X., Wu, X., & Wang, B. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.01.006 · Cited by 137
Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy
Itoh, N., Ohta, H., & Konishi, M. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00154 · Cited by 129
“FGF21 variant (LY2405319) Obesity and metabolic disease (91, 92)”
BackgroundCellular and molecular mechanisms in fibrosis
Dees, C., Chakraborty, D., & Distler, J. H. W. (2020) · Experimental Dermatology · doi:10.1111/exd.14193 · Cited by 121
Stanislaus, S., Hecht, R., Yie, J., Hager, T., Hall, M., Spahr, C., Wang, W., Weiszmann, J., Li, Y., Deng, L., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1917 · Cited by 115
FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
Kharitonenkov, A., & DiMarchi, R. D. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.007 · Cited by 118
“Diet-induced obese (DIO) mice [41] and monkeys [90] when treated with FGF21 lose weight in a precipitous manner, to a point of near normalization.”
Self-citationFGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases
Sonoda, J., Chen, M. Z., & Baruch, A. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0002 · Cited by 105
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 100
Self-citationBaruch, A., Wong, C., Chinn, L. W., Vaze, A., Sonoda, J., Gelzleichter, T., Chen, S., Lewin-Koh, N., Morrow, L., Dheerendra, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012073117 · Cited by 95
Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges
Martínez‐Garza, Ú., Torres‐Oteros, D., Yarritu, A., Marrero, P. F., Haro, D., & Relat, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194692 · Cited by 96
FGF19 and FGF21: In NASH we trust
Talukdar, S., & Kharitonenkov, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101152 · Cited by 97
“Food consumption in this study was decreased by more than 50%, suggestive of decreased caloric intake being the primary mechanism, leading to weight loss in higher species [101].”
BackgroundSelf-citationFibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
So, W. Y., & Leung, P. S. (2016) · Medicinal Research Reviews · doi:10.1002/med.21390 · Cited by 93
Goedeke, L., Perry, R. J., & Shulman, G. I. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104727 · Cited by 77
Phan, P., Saikia, B. B., Sonnaila, S., Agrawal, S., Alraawi, Z., Kumar, T. K. S., & Iyer, S. (2021) · Cells · doi:10.3390/cells10092418 · Cited by 78
The potential function and clinical application of FGF21 in metabolic diseases
Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., & Zheng, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1089214 · Cited by 76
“1 LY2405319 LY2405319, an FGF21 analog developed by Lilly Research Laboratories in 2013, has shown the same efficacy and biological activity as native human FGF21 (Adams et al., 2013; Gaich et al., 2013).”
BackgroundResultCurrent status and future perspectives of FGF21 analogues in clinical trials
Chui, Z. S. W., Shen, Q., & Xu, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.001 · Cited by 73
“Motivated by the compelling pharmacological effects of FGF21 on the reduction of fat mass, body weight, and blood glucose in preclinical studies [36,37], early forays into clinical trials aimed to evaluate the primary outcomes of FGF21 analogues on the treatment of obesity and T2DM.”
BackgroundJin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension
Huang, Z. P., Xu, A., & Cheung, B. M. Y. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0730-5 · Cited by 78
Babaknejad, N., Nayeri, H., Hemmati, R., Bahrami, S., & Esmaillzadeh, A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0623-2909 · Cited by 71
“A significant reduction in plasma glucose, and insulin levels, as well as body weight has been reported through administering FGF21 and/or FGF21 analogue in a non-human primate diabetes model [105, 106].”
BackgroundMethodFibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang, J., & Li, Y. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00168 · Cited by 70
“The avimer fusion molecule, FGF21 (1-171)-WD22, indeed has improved properties and decreased susceptibility to modifications compared to wild-type FGF21 (78), providing a novel framework for further engineering that is not possible with the wild-type protein.”
BackgroundWeng, Y., Chabot, J. R., Bernardo, B., Yan, Q., Zhu, Y., Brenner, M. B., Vage, C., Logan, A., Calle, R., & Talukdar, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119104 · Cited by 67
“In non-human primates, an FGF21 analog causes a marked reduction in food intake [34], although a monoclonal antibody against KLB/FGFR1c does not appear to cause significant changes in food intake, although imparting robust weight loss [5].”
BackgroundFGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 71
“…reported no difference of glucose intolerance between in Fgf21K/K mice and Fgf21C/C Published by Bioscientifica Ltd. Downloaded from Bioscientifica.com at 12/03/2018 01:21:31PM via free access Jo u rn a l o f E n d o cr in o lo g y mice fed HFD (Fisher et al. 2010, Adams et al. 2013a).”
BackgroundInfluentialAndersen, B., Straarup, E. M., Heppner, K. M., Takahashi, D. L., Raffaele, V., Dissen, G. A., Lewandowski, K., Bödvarsdottir, T. B., Raun, K., Grove, K. L., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0080-7 · Cited by 66
“other studies that showed a decrease in leptin in response to FGF21 treatment of NHPs [12, 14].”
InfluentialKouroumalis, E., Voumvouraki, A., Augoustaki, A., & Samonakis, D. N. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i1.6 · Cited by 70
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
Aaldijk, A. S., Verzijl, C. R. C., Jonker, J. W., & Struik, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150222 · Cited by 70
Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues
Lin, X., Liu, Y. B., & Hu, H. (2017) · Biomedical Reports · doi:10.3892/br.2017.890 · Cited by 62
“However, the continuous glucose‑lowering effect of LY on the subject is insignificant compared with that of FGF21 in rodents and monkeys with diabetes mellitus, which is potentially due to individual differences and small sample sizes (8,13,82).”
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Laeger, T., Baumeier, C., Wilhelmi, I., Würfel, J., Kamitz, A., & Schürmann, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4389-x · Cited by 60
“In contrast to a few studies suggesting FGF21 resistance, numerous studies [20, 26, 31, 32] conducted in obese animals, which may have impaired”
ResultLiu, J., Foo, J. P., Liu, S., & Lim, S. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.032 · Cited by 61
“[49] Adams AC, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, et al.”
BackgroundChen, M. Z., Chang, J. C., Zavala-Solorio, J., Kates, L., Thai, M., Ogasawara, A., Bai, X., Flanagan, S., Nunez, V., Phamluong, K., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.003 · Cited by 58
Zhang, Y., Zhao, X., Dong, X., Zhang, Y., Zou, H., Jin, Y., Guo, W., Zhai, P., Chen, X., & Kharitonenkov, A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.001 · Cited by 60
Self-citationThe regulation of FGF21 gene expression by metabolic factors and nutrients
Erickson, A., & Moreau, R. F. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0016 · Cited by 65
The nonhuman primate as a model for type 2 diabetes
Pound, L. D., Kievit, P., & Grove, K. L. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000043 · Cited by 59
Cui, A., Li, J., Ji, S., Ma, F., Wang, G., Xue, Y., Liu, Z., Gao, J., Han, J., Tai, P., et al. (2020) · Diabetes · doi:10.2337/db20-0209 · Cited by 56
“Consistent with the previous reports (18,28,30), B1344 administration decreased fasting blood glucose after 8 days of treatment, and 1 mg/kg BIW and 2 mg/kg BIW dosing decreased it significantly (Supplementary Fig.”
ResultGliniak, C. M., Gordillo, R., Youm, Y., Lin, Q., Crewe, C., Zhang, Z., Field, B. C., Fujikawa, T., Virostek, M., Zhao, S., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.011 · Cited by 59
The Roles and Pharmacological Effects of FGF21 in Preventing Aging-Associated Metabolic Diseases
Yan, J., Nie, Y., Cao, J., Luo, M., Yan, M., Chen, Z., & He, B. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.655575 · Cited by 56
“FGF21 has beneficial pharmacological effects on T2DM, obesity, and NAFLD, and a large number of preclinical studies have been reported (99, 130).”
BackgroundUpdate on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.
Liu, H., & Peng, D. (2022) · PubMed Central · doi:10.1530/ec-21-0002 · Cited by 53
“When treated with recombinant FGF21, serum TG, VLDL-C and LDL-C of rodents significantly reduced (65, 66).”
Kim, J. ‐., Bae, K. ‐., Choi, Y. ‐., Go, Y., Choe, M., Jeon, Y. ‐., Lee, H. ‐., Koo, S. ‐., Perfield, J. W., Harris, R. A., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12408 · Cited by 50
“Fibroblast growth factor 21 (FGF21) is a secreted protein that has been shown to regulate glucose, lipid and energy metabolism and, consequently, is under evaluation for the treatment of a range of metabolic disorders including obesity and T2DM [5–9].”
Thompson, W. C., Zhou, Y., Talukdar, S., & Musante, C. J. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9481-1 · Cited by 49
“While pair-feeding data are strongly suggestive that PF-05231023 acts primarily to reduce food intake, the compound is known to cause increases in energy expenditure in mice [12]; moreover, there are conflicting reports regarding the effects on energy balance of other compounds targeting the FGF21 axis [8, 9].”
BackgroundResultHepatic hormone FGF21 and its analogues in clinical trials
Shao, W., & Jin, T. (2022) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2021.08.005 · Cited by 55
“LY2405319 is an engineered human FGF21 variant produced in the fungus Pichia pastoris with improved formulation stability and protein expression.(38,44,45) PF‐05231023 is a long‐acting FGF21 analogue, which contains two modified human FGF21 molecules that are linked to a humanized immunoglobulin 1 antibody backbone.”
BackgroundRiera, C. E., & Dillin, A. G. (2015) · Nature Medicine · doi:10.1038/nm.4005 · Cited by 53
Bernardo, B., Lu, M., Bandyopadhyay, G., Li, P., Zhou, Y., Huang, J., Levin, N., Tomas, E. M., Calle, R. A., Erion, D. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11382 · Cited by 48
Liu, X., Zhang, P., Martin, R. C. G., Cui, G., Wang, G., Tan, Y., Cai, L., Lv, G., & Li, Y. (2016) · PubMed · Cited by 52
Metabolic roles of endocrine fibroblast growth factors
Fernandes-Freitas, I., & Owen, B. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.014 · Cited by 50
Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
Agrawal, A., Parlee, S. D., Pérez–Tilve, D., Li, P., Pan, J. H., Mroz, P. A., Hansen, A. M. K., Andersen, B., Finan, B., Kharitonenkov, A., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.003 · Cited by 47
“Indeed, doseproportional glucose lowering was observed in diabetic, non-human primates in an acute manner but only at supra-pharmacologic levels, beyond those clinically tested [31,32].”
BackgroundSelf-citationStemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J. F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3668-7 · Cited by 44
“Nevertheless, the pharmacological application of FGF21 holds promise as an effective therapeutic means for treating obesity and diabetes [20–25] despite uncertainty remaining regarding its physiological role as endocrine mediator of ketogenic adaptations.”
BackgroundZhang, J., & Li, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.007 · Cited by 44
FGF21 and Chronic Kidney Disease
Salgado, J. V., Góes, M. Â., & Filho, N. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154738 · Cited by 48
Fibroblast growth factor 21 in metabolic syndrome
Yang, M., Liu, C., Jiang, N., Liu, Y., Luo, S., Li, C., Zhao, H., Han, Y., Chen, W., Li, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1220426 · Cited by 46
“Another FGF21 mimetic, LY2405319, also showed signi fi cant weight loss in rhesus monkeys (69).”
BackgroundIzaguirre, M., Gil, M. J., Monreal, I., Montecucco, F., Frühbeck, G., & Catalán, V. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0866-3 · Cited by 44
Liver Brain Interactions: Focus on FGF21 a Systematic Review
Prida, E., Álvarez-Delgado, S., Pérez-Lois, R., Soto-Tielas, M., Estany‐Gestal, A., Fernø, J., Seoane, L. M., Quiñones, M., & Al–Massadi, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113318 · Cited by 42
“2013; Adams [59] DIO Mice Peripheral SC FGF21 analogue, LY2405319 Reduction of BW Reduces plasma glucose and insulin and improves lipid profile”
BackgroundFibroblast growth factor 21 in chronic kidney disease
Anuwatmatee, S., Tang, S., Wu, B. J., Rye, K.-A., & Ong, K. L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.11.002 · Cited by 40
Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies
Hua, S., Liu, Q., Li, J., Fan, M., Yan, K., & Ye, D. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09661-1 · Cited by 40
Claflin, K. E., Sullivan, A. I., Naber, M. C., Flippo, K. H., Morgan, D. A., Neff, T. J., Jensen-Cody, S. O., Zhu, Z., Zingman, L. V., Rahmouni, K., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101564 · Cited by 44
“In addition, in non-human primates and humans, who have brown adipose tissue but do not depend as heavily on brown adipose tissue thermogenesis to regulate whole body energy homeostasis, FGF21 may promote weight loss, at least in part, by regulating food intake [18,55,56].”
BackgroundNutrition, metabolism, and targeting aging in nonhuman primates
Balasubramanian, P., Mattison, J. A., & Anderson, R. M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.002 · Cited by 49
Le, C. T., Nguyen, G., Park, S. Y., Choi, D. H., & Cho, E.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192146 · Cited by 36
Beige Fat, Adaptive Thermogenesis, and Its Regulation by Exercise and Thyroid Hormone
Phillips, K. J. (2019) · Biology · doi:10.3390/biology8030057 · Cited by 38
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 34
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 34
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
Shi, S. Y., Lu, Y., Richardson, J., Min, X., Weiszmann, J., Richards, W. G., Wang, Z., Zhang, Z., Zhang, J., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-29396-5 · Cited by 35
Girer, N. G., Carter, D., Bhattarai, N., Mustafa, M. G., Denner, L. A., Porter, C. C., & Elferink, C. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040950 · Cited by 32
A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog
Song, L., Zhu, Y., Wang, H., Belov, A. A., Niu, J., Shi, L., Xie, Y., Ye, C., Li, X., & Huang, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.023 · Cited by 33
Nuclear receptors and AMPK: can exercise mimetics cure diabetes?
Wall, C. E., Yu, R. T., Atkins, A. R., Downes, M., & Evans, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0073 · Cited by 32
Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases
Cheung, B. M. Y., & Deng, H. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.904745 · Cited by 35
“LY2405319 Lilly Amino acid changes Unchanged [14,15] PEG FGF21 Ambrx/Merck Coupling to PEG Increased [67] Fc-FGF21(RG) Amgen Fusion to Fc Increased [71] CVX-343 Pfizer Coupling to Ab Increased [72] FGFR1b/1c agonist antibody Genentech Ab Increased [73] mimAb1 agonist antibody Amgen Ab Increased [74] FGFR1c/b-Klotho bi…”
BackgroundNovel insights into the pathological development of dyslipidemia in patients with hypothyroidism
Su, X., Chen, X., Peng, H., Song, J., Wang, B., & Wu, X. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2021.6606 · Cited by 34
“Recently, two independent researchers using mice which were treated with recombinant FGF-21 protein and found that the serum concentrations of TG, VLDL-C, and LDL-C were significantly reduced in rodents [50,51].”
BackgroundDiscovery of Novel Insulin Sensitizers: Promising Approaches and Targets
Chen, Y., Ma, H., Dasheng, Z., Zhao, G., Wang, L., Fu, X., & Chen, W. (2017) · PPAR Research · doi:10.1155/2017/8360919 · Cited by 31
“In addition, LY2405319, an engineered FGF21 variant, has recently been found to be effective in alleviating IR in diabetic mice and monkeys [73, 74].”
BackgroundChen, X. Y., Li, G. M., Dong, Q., & Peng, H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.november.30.24 · Cited by 31
“However, ERK1/2 need not be activated to stimulate insulin secretion (Adams et al., 2013; Gaich et al., 2013).”
BackgroundUse of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
Carbonetti, M. P., Almeida‐Oliveira, F., & Majerowicz, D. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2022-0493 · Cited by 26
“Similarly, the FGF21 analog LY2405319 reduced fasting blood insulin in ApoE -/- mice on an atherogenic diet and insulin levels in diabetic monkeys (28,62).”
BackgroundResultInfluentialAdvances in Biological Functions and Clinical Studies of FGF21
Lin, W. J., Zhang, T., Zhou, Y., Zheng, J., & Lin, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s317096 · Cited by 24
Nutritional Regulation of Hepatic FGF21 by Dietary Restriction of Methionine
Fang, H., Stone, K. P., Forney, L. A., Wanders, D., & Gettys, T. W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.773975 · Cited by 27
Fibroblast Growth Factor 21 Facilitates the Homeostatic Control of Feeding Behavior
Wu, C.-T., CHAFFIN, A. T. B., & Ryan, K. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030580 · Cited by 24
Shi, X., Zheng, Q., Wang, X., Guo, W., Lin, Z., Gao, Y., Shore, E. A., Martin, R. C. G., Lv, G., & Li, Y. (2024) · Science Advances · doi:10.1126/sciadv.ado9311 · Cited by 23
Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities
Li, J., Duan, H., Liu, Y., Wang, L., & Zhou, X. W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071445 · Cited by 23
Alpha lipoic acid induces hepatic fibroblast growth factor 21 expression via up-regulation of CREBH
Bae, K.-H., Min, A.-K., Kim, J., Lee, I., & Park, K. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.147 · Cited by 25
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 23
Metadata
- Authors
- Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A.
- Affiliations
- Eli Lilly (United States) (US)
- University of South Florida (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-18
- Volume
- 8
- Issue
- 6
- Pages
- e65763
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3688819
- OpenAlex
- W1972717747
- Cited by
- 169
- References
- 24
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 8 · 2019: 12 · 2018: 10 · 2017: 17 · 2016: 12 · 2015: 22 · 2014: 11 · 2013: 3
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21 analogues, FGF21, type 2 diabetes, rhesus monkeys, glycemic control, lipid lowering, adiponectin, leptin, adipose tissue, insulin
- MeSH terms
- Animals, Blood Glucose, Energy Intake, Diabetes Mellitus, Experimental, Dose-Response Relationship, Drug, Fibroblast Growth Factors, Insulin, Macaca mulatta, Weight Loss, Disease Progression, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.